Xiaoyu Zhang1,2, Rongxia Guo3, Hiroto Kambara1,2, Fengxia Ma3, Hongbo R Luo1,2. 1. Department of Pathology, Harvard Medical School. 2. Department of Lab Medicine, The Stem Cell Program, Boston Children's Hospital, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA. 3. The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Abstract
PURPOSE OF REVIEW: CXCR2 is key stimulant of immune cell migration and recruitment, especially of neutrophils. Alleviating excessive neutrophil accumulation and infiltration could prevent prolonged tissue damage in inflammatory disorders. This review focuses on recent advances in our understanding of the role of CXCR2 in regulating neutrophil migration and the use of CXCR2 antagonists for therapeutic benefit in inflammatory disorders. RECENT FINDINGS: Recent studies have provided new insights into how CXCR2 signaling regulates hematopoietic cell mobilization and function in both health and disease. We also summarize several CXCR2 regulatory mechanisms during infection and inflammation such as via Wip1, T-bet, P-selectin glycoprotein ligand-1, granulocyte-colony-stimulating factor, and microbiome. Moreover, we provide an update of studies investigating CXCR2 blockade in the laboratory and in clinical trials. SUMMARY: Neutrophil homeostasis, migration, and recruitment must be precisely regulated. The CXCR2 signaling pathway is a potential target for modifying neutrophil dynamics in inflammatory disorders. We discuss the recent clinical use of CXCR2 antagonists for controlling inflammation.
PURPOSE OF REVIEW: CXCR2 is key stimulant of immune cell migration and recruitment, especially of neutrophils. Alleviating excessive neutrophil accumulation and infiltration could prevent prolonged tissue damage in inflammatory disorders. This review focuses on recent advances in our understanding of the role of CXCR2 in regulating neutrophil migration and the use of CXCR2 antagonists for therapeutic benefit in inflammatory disorders. RECENT FINDINGS: Recent studies have provided new insights into how CXCR2 signaling regulates hematopoietic cell mobilization and function in both health and disease. We also summarize several CXCR2 regulatory mechanisms during infection and inflammation such as via Wip1, T-bet, P-selectin glycoprotein ligand-1, granulocyte-colony-stimulating factor, and microbiome. Moreover, we provide an update of studies investigating CXCR2 blockade in the laboratory and in clinical trials. SUMMARY: Neutrophil homeostasis, migration, and recruitment must be precisely regulated. The CXCR2 signaling pathway is a potential target for modifying neutrophil dynamics in inflammatory disorders. We discuss the recent clinical use of CXCR2 antagonists for controlling inflammation.
Authors: Jakob Busch-Petersen; Donald C Carpenter; Miriam Burman; James Foley; Gerald E Hunsberger; David J Kilian; Michael Salmon; Ruth J Mayer; John G Yonchuk; Ruth Tal-Singer Journal: J Pharmacol Exp Ther Date: 2017-06-13 Impact factor: 4.030
Authors: Daiane Boff; Vivian L S Oliveira; Celso M Queiroz Junior; Tarcília A Silva; Marcelo Allegretti; Waldiceu A Verri; Paul Proost; Mauro M Teixeira; Flavio A Amaral Journal: Eur J Immunol Date: 2018-01-09 Impact factor: 5.532
Authors: Anja Köhler; Katia De Filippo; Mike Hasenberg; Cindy van den Brandt; Emma Nye; Martin P Hosking; Thomas E Lane; Linda Männ; Richard M Ransohoff; Anja E Hauser; Oliver Winter; Burkhart Schraven; Hartmut Geiger; Nancy Hogg; Matthias Gunzer Journal: Blood Date: 2011-01-11 Impact factor: 22.113
Authors: Paul M O'Byrne; Hristo Metev; Margareta Puu; Kai Richter; Christina Keen; Mohib Uddin; Bengt Larsson; Marie Cullberg; Parameswaran Nair Journal: Lancet Respir Med Date: 2016-08-27 Impact factor: 30.700
Authors: Marie Cullberg; Cecilia Arfvidsson; Bengt Larsson; Anna Malmgren; Patrick Mitchell; Ulrika Wählby Hamrén; Heather Wray Journal: Drugs R D Date: 2018-06
Authors: Sung Kyun Lee; Sang Doo Kim; Minsoo Kook; Ha Young Lee; Jaewang Ghim; Youngwoo Choi; Brian A Zabel; Sung Ho Ryu; Yoe-Sik Bae Journal: J Exp Med Date: 2015-08-17 Impact factor: 14.307
Authors: Jubin P Joseph; Eliana Reyes; Josephine Guzman; Jim O'Doherty; Hannah McConkey; Satpal Arri; Rahul Kakkar; Nicholas Beckley; Abdel Douiri; Sally F Barrington; Simon R Redwood; Albert Ferro Journal: Trials Date: 2017-10-11 Impact factor: 2.279
Authors: Md Jahangir Alam; Liang Xie; Caroline Ang; Farnaz Fahimi; Stephen B Willingham; Andrew J Kueh; Marco J Herold; Charles R Mackay; Remy Robert Journal: MAbs Date: 2020 Jan-Dec Impact factor: 5.857